Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is a cholinesterase inhibitor presented as an oral formulation for oral use. It increases acetylcholine availability at the neuromuscular junction and is used to improve muscle strength in patients with myasthenia gravis and to aid recovery of bowel motility after surgery.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets, with a focus on timely delivery and support for regulatory documentation.

Mestinon acts on the cholinergic neuromuscular pathway and is indicated for the following conditions: - Myasthenia gravis: improves skeletal muscle strength and reduces fatigue in affected patients. - Postoperative ileus: stimulates gastrointestinal motility to restore normal bowel function after abdominal surgery.

Mestinon may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased intestinal motility. - Abdominal cramps: discomfort in the abdomen. - Excessive salivation: drooling or watery mouth. - Muscle cramps: involuntary tightening of muscles. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Cholinergic crisis: severe muscle weakness and respiratory compromise. - Bradycardia: markedly slow heart rate. - Bronchospasm: narrowing of airways causing breathing difficulty. - Seizures: rare central nervous system events. - Allergic reactions: rash, itching, or anaphylaxis. - Severe hypotension: sudden drop in blood pressure.

Before initiating therapy with Mestinon, consider the following safety measures: - Dose adjustment: reduce dose in patients with renal impairment. - Cardiac monitoring: observe for bradycardia or heart block in susceptible individuals. - Gastrointestinal caution: monitor for severe diarrhea or abdominal pain. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Concomitant cholinergic agents: avoid additive effects that may precipitate cholinergic crisis. - Store at ambient temperature: keep below 25°C, retain in the original container, and protect from moisture.

Mestinon can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Beta‑blockers: may exacerbate bradycardia. - Other cholinergic agents (e.g., neostigmine): additive cholinergic effects can lead to crisis. - Magnesium sulfate: potentiates neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: may diminish pyridostigmine efficacy. - Loop diuretics (e.g., furosemide): can increase pyridostigmine plasma levels. - Antihypertensives (e.g., ACE inhibitors): monitor blood pressure for additive hypotensive effect.